Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Omics studies produce a large number of measurements, enabling the development, validation and interpretation of systems-level biological models. Large cohorts are required to power these complex models; yet, the cohort size remains limited due to clinical and budgetary constraints. We introduce clinical and omics multimodal analysis enhanced with transfer learning (COMET), a machine learning framework that incorporates large, observational electronic health record databases and transfer learning to improve the analysis of small datasets from omics studies. By pretraining on electronic health record data and adaptively blending both early and late fusion strategies, COMET overcomes the limitations of existing multimodal machine learning methods. Using two independent datasets, we showed that COMET improved the predictive modelling performance and biological discovery compared with the analysis of omics data with traditional methods. By incorporating electronic health record data into omics analyses, COMET enables more precise patient classifications, beyond the simplistic binary reduction to cases and controls. This framework can be broadly applied to the analysis of multimodal omics studies and reveals more powerful biological insights from limited cohort sizes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11847705PMC
http://dx.doi.org/10.1038/s42256-024-00974-9DOI Listing

Publication Analysis

Top Keywords

electronic health
16
machine learning
12
omics studies
12
health record
12
analysis omics
8
transfer learning
8
record data
8
omics
7
analysis
5
learning approach
4

Similar Publications

Background: Hospital-acquired venous thromboembolism (HA-VTE) is a leading cause of morbidity and mortality among hospitalized adults. Numerous prognostic models have been developed to identify those patients with elevated risk of HA-VTE. None, however, has met the necessary criteria to guide clinical decision-making.

View Article and Find Full Text PDF

Background: The concept of early-phase diffuse idiopathic skeletal hyperostosis (EDISH) was recently introduced and its prevalence at the thoracic spine level was revealed. Some cases of EDISH progress to diffuse idiopathic skeletal hyperostosis (DISH) in association with being overweight. The prevalence and distribution of EDISH in the whole spine and related factors are unclear.

View Article and Find Full Text PDF

Background: Combination therapy with enfortumab vedotin plus pembrolizumab (EV+P) is now the preferred first-line (1L) therapy for advanced urothelial carcinoma (aUC), but prognostic indicators for patients on 1L EV+P have not yet been described.

Patients And Methods: We conducted a retrospective cohort study of patients receiving 1L EV+P for aUC. We analyzed deidentified electronic health record data from the Flatiron Health database to identify adults with aUC who initiated EV+P between April 3, 2023 and December 31, 2024.

View Article and Find Full Text PDF

The GPR120 agonist TUG-891 mitigates ischemic brain injury by attenuating endoplasmic reticulum stress and apoptosis via the PI3K/AKT signaling pathway.

Neurotherapeutics

September 2025

Department of Neurology, Peking University Third Hospital, Beijing, 100191, China; Beijing Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, 100191, China; Key Laboratory for Neuroscience, National Health Commission/Ministry of Education, Peking Universit

Extensive research has confirmed that omega-3 fatty acids provide cardiovascular protection primarily by activating the G protein-coupled receptor 120 (GPR120) signaling pathway. However, natural activators of this receptor often lack sufficient strength and precision. TUG-891, a recently synthesized selective GPR120 activator, has displayed significant therapeutic potential in multiple disease.

View Article and Find Full Text PDF

Comparison of clinical manifestations, antimicrobial susceptibility patterns, and carbapenem resistance determinants between Acinetobacter seifertii and Acinetobacter nosocomialis isolated in Taiwan.

J Microbiol Immunol Infect

August 2025

Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. Electronic address:

Background: Acinetobacter seifertii, a recently identified member of the Acinetobacter calcoaceticus-Acinetobacter baumannii (Acb) complex, has emerged as a cause of severe human infections. It is closely related to Acinetobacter nosocomialis, a major pathogen of the Acb complex. Here, we aimed to explore the clinical and molecular differences between these two species.

View Article and Find Full Text PDF